2m 2m 2m 2m 2m 2m 2m
ANI Pharmaceutic (ANIP)
NASDAQ
$70.22+$0.03 (+0.04%)
Price as of Sep 11, 2026 7:30 PM EDT- $1.6BMarket Cap
- -28.16%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
ANI Pharmaceutic (ANIP)
$70.22+$0.03 (+0.04%)
Top Holders
Institutional
Mutual Funds
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
BLACKROCK, INC. | 13.01% | 3.0M | +211,154 (+7.14%) | Jun 30, 2026 |
BLACKROCK FUNDING, INC. /DE | 12.05% | 2.7M | +48,860 (+1.78%) | Dec 31, 2024 |
BLACKROCK INC. | 11.68% | 2.7M | +125,172 (+4.71%) | Jun 30, 2024 |
VANGUARD GROUP INC | 5.74% | 1.3M | +27,598 (+2.11%) | Dec 31, 2025 |
SOLEUS CAPITAL MANAGEMENT, L.P. | 3.82% | 867,760 | +47,517 (+5.48%) | Jun 30, 2026 |
VANGUARD CAPITAL MANAGEMENT LLC | 3.69% | 838,224 | +15,160 (+1.81%) | Jun 30, 2026 |
STATE STREET CORP | 3.66% | 831,647 | +60,060 (+7.22%) | Jun 30, 2026 |
Holder | Ownership %
| Shares Held | Change (Shares, %) | Report Date |
|---|---|---|---|---|
iSHARES TRUST | 9.05% | 2.1M | +129,070 (+6.27%) | Jun 30, 2026 |
BANCROFT FUND LTD | 8.80% | 2.0M | 0 (0.00%) | Jun 30, 2026 |
ELLSWORTH GROWTH & INCOME FUND LTD | 8.80% | 2.0M | 0 (0.00%) | Jun 30, 2026 |
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC | 4.62% | 1.1M | 0 (0.00%) | Jun 30, 2026 |
VANGUARD INDEX FUNDS | 3.60% | 818,536 | +15,963 (+1.95%) | Jun 30, 2026 |
BNY Mellon Absolute Insight Funds, Inc. | 3.08% | 700,000 | 0 (0.00%) | Apr 30, 2026 |
AMERICAN CENTURY ETF TRUST | 1.81% | 412,268 | +316,832 (+76.85%) | May 31, 2026 |
Current Ownership Distribution
- Institutions295.6M (70.05%)
- Mutual Funds119.0M (28.19%)
- Insiders7.5M (1.77%)
- Other0 (0.00%)
Insider Transactions
- 1.77% (7.5M)Current InsiderOwnership (%, shares)
- 0Number of InsiderBuying (last 12 months)
- $0.00Amount of InsiderBuying (last 12 months)
- 8Number of InsiderSelling (last 12 months)
- $198.0MAmount of InsiderSelling (last 12 months)
Insider Name & Title | Type | Date
| Transaction Value | Shares | Share Price | Shares After Transactions |
|---|---|---|---|---|---|---|
CAREY STEPHEN P. SVP & CFO | Sell | Aug 31, 2026 | $207,480.00 | 2,850 | $72.80 | 171,843 |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sell | Aug 13, 2026 | $37,740.00 | 500 | $75.48 | 74,424 |
CAREY STEPHEN P. SVP & CFO | Sell | Jul 29, 2026 | $231,876.00 | 2,850 | $81.36 | 174,693 |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sell | Jul 13, 2026 | $40,920.00 | 500 | $81.84 | 77,390 |
CAREY STEPHEN P. SVP & CFO | Sell | Jun 29, 2026 | $239,742.00 | 2,850 | $84.12 | 177,543 |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sell | Jun 12, 2026 | $41,015.00 | 500 | $82.03 | 77,890 |
HAUGHEY THOMAS | Sell | Jun 08, 2026 | $161,760.00 | 2,000 | $80.88 | 38,878 |
Thoma Jeanne | Award | May 21, 2026 | $0.00 | 4,357 | $0.00 | 27,762 |
TANNENBAUM RENEE P | Award | May 21, 2026 | $0.00 | 4,357 | $0.00 | 29,514 |
HAUGHEY THOMAS | Award | May 21, 2026 | $0.00 | 4,357 | $0.00 | 40,878 |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sell | Mar 13, 2026 | $36,310.00 | 500 | $72.62 | 79,390 |
Mutz Christopher HEAD OF RARE DISEASE | Sell | Mar 13, 2026 | $226,525.68 | 3,162 | $71.64 | 91,309 |
Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS | Sell | Mar 11, 2026 | $357,470.52 | 4,772 | $74.91 | 38,730 |
Mutz Christopher HEAD OF RARE DISEASE | Sell | Mar 09, 2026 | $267,196.36 | 3,602 | $74.18 | 94,471 |
Davis Krista SVP, CHIEF HR OFFICER | Sell | Mar 09, 2026 | $377,099.31 | 5,087 | $74.13 | 51,946 |
Mutz Christopher HEAD OF RARE DISEASE | In Kind | Mar 07, 2026 | $245,368.56 | 3,314 | $74.04 | 98,073 |
Lalwani Nikhil PRESIDENT & CEO | In Kind | Mar 07, 2026 | $1.3M | 17,060 | $74.04 | 404,889 |
CAREY STEPHEN P. SVP & CFO | In Kind | Mar 07, 2026 | $381,306.00 | 5,150 | $74.04 | 180,393 |
Mutz Christopher HEAD OF RARE DISEASE | Sell | Mar 06, 2026 | $157,420.62 | 2,121 | $74.22 | 101,387 |
Davis Krista SVP, CHIEF HR OFFICER | Sell | Mar 06, 2026 | $111,375.00 | 1,485 | $75.00 | 57,033 |
CAREY STEPHEN P. SVP & CFO | Exempt | Mar 05, 2026 | $163,977.12 | 3,312 | $49.51 | 9,938 |
CAREY STEPHEN P. SVP & CFO | Exempt | Mar 05, 2026 | $163,977.12 | 3,312 | $49.51 | 192,855 |
CAREY STEPHEN P. SVP & CFO | Sell | Mar 05, 2026 | $249,791.04 | 3,312 | $75.42 | 189,543 |
CAREY STEPHEN P. SVP & CFO | Sell | Mar 05, 2026 | $302,240.00 | 4,000 | $75.56 | 185,543 |
Walsh Patrick D | Sell | Mar 03, 2026 | $445,380.00 | 6,000 | $74.23 | 52,405 |
Gutwerg Ori SVP, GENERICS | Sell | Mar 03, 2026 | $157,590.00 | 2,060 | $76.50 | 84,782 |
Mutz Christopher HEAD OF RARE DISEASE | Sell | Mar 02, 2026 | $30,858.00 | 417 | $74.00 | 103,508 |
Lalwani Nikhil PRESIDENT & CEO | In Kind | Feb 28, 2026 | $902,836.30 | 12,217 | $73.90 | 421,949 |
Gassert Chad SVP - CORP. DEV. & STRATEGY | In Kind | Feb 28, 2026 | $164,131.90 | 2,221 | $73.90 | 74,916 |
Gutwerg Ori SVP, GENERICS | In Kind | Feb 28, 2026 | $164,131.90 | 2,221 | $73.90 | 86,842 |